242791US0CONT/p

## IN THE UNITED STAFFES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Tetsuya SUGA, et al.

SERIAL NO:

10/692,684

GAU:

1616

FILED:

October 27, 2003

EXAMINER:

FOR:

IMMUNE ACTIVATOR

# , INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

The applicant(s) wish to make of record the references, some of which are cited in the attached European Search Report listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### **RELATED CASES**

Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. In accordance with discussions on August 4, 2004 with Mr. Nicholas P. Godici, Commissioner for Patents, it is no longer required to submit copies of cited pending applications. A modification of the Rules will be published soon in the Official Gazette. Cited issued patents, if any, are listed on the attached PTO form 1449.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

□ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Vincent K. Shier, Ph.D. Registration No. 50,552

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO. 242791US0CONT		SERIAL NO.	
(Modified)		PATENT AND TRAI	DEMARK OFFICE	242791US0CONT		10/692,684	
		·		APPLICANT			
LIST OF REFERENCES CITED BY APPLICANT  Tetsuya SUGA, et al.							
				FILING DATE		GROUP	
				October 27, 2003		1616	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2001/0000229 A1	04/12/2001	K. TAZAWA, et al.			
	AB	5,849,720	12/15/1998	S. JAMAS, et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	АН					-	
	Al						-
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	AO	30 19 614	12/03/1981	GERMANY			X
	AP	199 44 695	03/30/2000	GERMANY			X
	AQ	1 356 449	06/12/1974	GREAT BRITAIN			
	AR	WO 02/12348	02/14/2002	WIPO			
	AS						
	AT						
Î	ΑU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	A. KASUGA, et al., Nippon Shokuhin Kogyo Gakkaishi, vol. 40, no. 1, pages 62-63, "ANTIOXIDATIVE ACTIVITIES OF SEVERAL MUSHROOM EXTRACTS", 1993 (pages 56-61 were filed on 08/11/04)						
	AX						
	AY						
	AZ			Additional References sheet(s) attached			
Examiner				*** \ \	Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in							
conformance	and no	t considered Include of	nny of this form	with next communication to applicant	,		